Navigation Links
Silymarin does not affect virus activity or ALT levels in
Date:2/1/2008

In a survey of patients with chronic hepatitis C who participated in a National Institute of Diabetes and Digestive and Kidney Diseases-sponsored long-term treatment trial for patients who had failed to respond previously to antiviral therapy, approximately 40% acknowledged to interviewers at the time of enrollment that they were currently using or had in the recent past used herbal products for health purposes. This information was somewhat surprising because these were patients with advanced liver disease who were clearly committed to conventional antiviral treatment for chronic hepatitis C, having been so treated previously, some on more than one occasion, but because they had failed to respond, were now willing to accept treatment again with pegylated interferon for another 3 and a half years. Among those who were or had used alternative therapies, silymarin (milk thistle) was the product of choice either on its own or together with other herbal products, representing 72% of all the herbals taken.

These findings are in the February issue of Hepatology, a journal published by Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article was also available online at Wiley Interscience (http://www.interscience.wiley.com/journal/hepatology).

These results do not come from a rigorous scientific study because the products used were self-administered by the patients who entered the trial and no information was obtained on the duration or dose of the herbal taken. Still, in comparing users with non-users, while no difference was found for blood ALT or HCV levels between the two groups, the herbal users did report somewhat fewer symptoms and a better quality of life.

The current recommended treatment for patients with HCV infection is combination therapy with pegylated interferon and ribavirin. However, it leads to a sustained virological response in only a third to a half of all patients with the predominant form of the infection in the U.S., namely genotype 1, and it can cause unpleasant and sometimes serious side effects. The NIH study, referred to as the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial, was designed, therefore, to treat persons with advanced chronic hepatitis C who had failed previous antiviral therapy with the hope that the long-term treatment would reduce progression of the chronic liver disease even if it did not affect the virus itself. The reason for interviewing enrollees in the trial was to determine the extent of use of alternative therapies in this committed group, since the popularity of herbal products has increased in the U.S., many HCV patients choosing to supplement, or even replace, the standard treatment with herbals. Silymarin (milk thistle extract) has been the most popular option for people with liver disease. Although it is the most frequent product utilized, silymarin has not been rigorously studied using accepted scientific approaches, and therefore such studies are clearly required and warranted.

For the present survey, researchers interviewed all HALT-C participants on past and current use of all prescription and non-prescription drugs, including herbal medications, dietary supplements and other botanical products. Of 1145 study participants, 56 percent said that they had never used herbal products, while 23 percent were using them currently, some 60 different varieties. Silymarin was by far the most common. Usage was higher among men, among non-Hispanic whites, and among the more highly educated. Interestingly, the researchers also found geographic disparities in silymarin usage. It was most popular in Colorado, Michigan and Southern California and least popular in Maryland and Massachusetts.

In comparing the clinical data of silymarin users and non-users, the researchers found that the levels of HCV RNA were not significantly different between silymarin users and non-users, indicating no effect on virus activity. Similarly, the product did not alter serum ALT levels, indicating no effect on hepatic inflammation. However, after adjusting for covariates, the data showed that silymarin users reported less fatigue, nausea, liver pain, anorexia, muscle and joint pain and better general health than non-users.

The better scores in a small number of symptoms among silymarin users compared to non-users are insufficient to support the value of this alternative therapy, the authors conclude. Compelling information can come only if a scientifically valid study is performed. Currently in progress, therefore, is a properly designed prospective, randomized, controlled trial in which a fully characterized, purified and standardized silymarin formulation is being evaluated, they report.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Cutting Salt Wont Affect Foods Safety
2. A childs IQ could be affected by maternal epilepsy
3. Sexual function affected by stem cell transplant according to long-term study
4. Family history of alcoholism affects response to drug used to treat heavy drinking
5. Obesity Wont Affect Seniors Memory
6. Genetic variation affects smoking cessation treatment
7. Schizophrenia candidate genes affect even healthy individuals
8. R rating might be unlikely to affect teens exposure to smoking in movies
9. Painful condition affecting kidney failure patients increases risk of death
10. Patients perceived cancer care unaffected by lower Medicare reimbursements
11. The Current Recall of Boy Scouts of Americas Plastic Badges Does Not Affect Embroidered Insignia, Badges & Awards Produced by Lion Brothers Company Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Peachtree City, GA (PRWEB) , ... February 08, 2016 , ... ... healthy and cavity-free. February is National Children’s Dental Health Month and family dentist Yvonne ... to 3 p.m. at Coast Dental , located next to Target at 1207 ...
(Date:2/8/2016)... Alexandria, Minn. (PRWEB) , ... February 08, 2016 ... ... introduces the BantamPro L top-load case packer for pouches, bags, and flow wrapped ... designed to help co-packers and specialty product manufacturers step up to semi-automatic or ...
(Date:2/8/2016)... ... February 08, 2016 , ... The ... has selected the latest beneficiary of their ongoing community enrichment program. The current ... in area schools. Donations are now being accepted at: http://www.angelsanddoves.com/donate.html . , ...
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try using ... the health benefits of integrating clay into a daily diet are numerous, as clay ... speaker, Perry A~ has since dedicated her life to learning about the benefits of ...
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... ... showing greater than 50% lower incidence rate of type 2 diabetes in the ... averages. ”It is time to make a change in public health,” states Carole ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016  Echo Therapeutics, Inc. ... company focused on non-invasive continuous glucose monitoring ... announced that it will host a webcast ... 2015 at 9:00 a.m. Eastern Time to ... corporate strategy, advancements in its CGM system, ...
(Date:2/8/2016)... -- http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced ... Equipment Market 2016-2020" report to their offering. ... announced the addition of the "Global Skin ... offering. --> Research and ... of the "Global Skin Protective Equipment Market ...
(Date:2/8/2016)... , Feb. 8, 2016   HighPoint ... November Research Group (NRG),s pharmacovigilance technology services division.  ... consulting services and an Oracle Argus Specialized partner, ... to Life Sciences companies. --> ... expands HighPoint,s life sciences capabilities and provides a ...
Breaking Medicine Technology: